[ad_1]
Jakarta, CNBC Indonesia – Up to 7 institutions in Indonesia are currently participating in the development of the red and white vaccine, 5 from universities and 2 from research institutions. Currently, the fastest progress is seen in research conducted by the Eijkman Institute, aiming to deliver vaccine seeds in the first quarter of 2021 to PT Bio Farma.
“Of all, the schedule is the fastest possible for the Eijkman Institute. We and the Eijkman Institute have communicated to develop recombinant protein. At Bio Farma, the recombinant protein is a platform developed for the previous vaccine, specifically for hepatitis B.” said the president and director of PT Bio Farma Honesti. Basyir at Commission IX DPR RI, Thursday (01/14/2021).
He mentioned that five universities had been involved in the development of vaccines, namely the University of Indonesia with DNA, RNA and virus-like particle platforms, then the Bandung Institute of Technology (ITB) with adenovirus and inactivated platforms. .
Meanwhile, Universitas Gadjah Mada (UGM) with recombinant protein and Universitas Airlangga Air use two platforms of adenovirus and adeno-associated virus (AAV). Then, LIPI developed a recombinant fusion protein.
According to our discussion, the schedule cannot be completed in 2021, so the Red and White Vaccine will not be included in the management of Covid-2021, but the plan is that if the seeds of the vaccine can reach us in the first quarter of 2021 we will process, characterize, clinical trials and other possibilities. in the third quarter of 2021, we can produce as part of Indonesia’s health independence, “he said.
Honesti said that until now the effectiveness of this vaccine is still unknown, for this it requires national resilience and does not depend on imported goods.
“Our experience of reliance on imported goods makes it difficult for us to get supplies,” he said.
Previously, the Minister of Health, Budi Gunadi Sadikin, gave an explanation of the latest advances in the red and white vaccine, which is still in phase one and the results are in the form of vaccine seeds. Subsequently, the vaccine seeds will be sent to the industry, namely Biofarma for their characterization, which is estimated to take 3-6 months.
If the fastest time is 3 months, it will proceed to the stage 1 to 3 clinical trial phase, which lasts between 1 and 2 years.
“For example, at least 3 months each, it could occur at the beginning of the second quarter of 2022. In our plan, this will be the next vaccine, because it is estimated that the current vaccine will start to run out of immunity in 2022,” said Budi Commission IX. DPR RI, Wednesday (01/13/2020).
He recognized that a commitment is needed to strengthen the budget for vaccine development, which will be delivered to various consortia. However, the plan does not exist yet and is still in the preparation of a budget, especially for researchers to obtain support in collaboration with universities.
[Gambas:Video CNBC]
(Roy / Roy)
